Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor
OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s97100
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2016
Authors
Publisher
Informa UK Limited